menu

Medical Industry Feature: Managing mCRC Based on Prognostic Factors

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Managing mCRC Based on Prognostic Factors

Managing mCRC Based on Prognostic Factors
RestartResume

BRAF mutation has important genetic, prognostic, and therapeutic implications for patients with metastatic colorectal cancer, as these studies show.

  • Overview

    This program is intended for healthcare professionals only and is supported by an independent educational grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

    Tune in as Professor Volker Heinemann shares his perspective on whether the Consensus Molecular Subtype is ready for clinical practice, the implications of the BRAF mutations, and the current and future advances in the management of patients with metastatic colorectal cancer (mCRC).

    GBPMLR/NONO/1019/0043c

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 3/30/20